I agree with your view on K. To me, K is worth more than the current sp all by itself. That's one reason why I have so many shares. But so far the market apparently disagrees.
Regarding B, there was no single dose arm in the previous trial...and all of the results for B and daptomycin were statistically the same. The mid level arm of B was "directionally" lower than daptomycin...about 8 points (89% v. 97%) if I recall correctly. The others were all quite close
News 
Market Data 
Discover 
